Q-omics provides the consensus-scored RPS4XP2 profile across patient tissues and cancer cell-line models. RPS4XP2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPS4XP2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPS4XP2 RNA expression shows 13,093 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, KIRC, and ACC as cancer lineages where RPS4XP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP2 survival associations across molecular data types. RPS4XP2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP2 RNA expression–survival associations across cancer types. High RPS4XP2 expression shows unfavorable associations in LUAD, but favorable associations in SKCM, CESC, LUSC, THCA and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPS4XP2 RNA expression.
This table summarizes RPS4XP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP2 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, THCA, READ and CHOL. The KIRC box plot shows higher RPS4XP2 RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p < 0.001).
This table shows molecular features associated with RPS4XP2 in patient tissues and cancer cell lines. In patient samples, RPS4XP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
